You just read:

Vantia Therapeutics Announces Positive Results From its Phase III EQUINOC Study, a Pivotal Trial with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia

News provided by

Vantia Therapeutics

Oct 03, 2017, 07:00 ET